Abiopharma

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Alterity Therapeutics Limited (ATHE) Files Form 6-K

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

BRAINSWAY (BWAY) Files Form 6-K

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China